STL Volume 25 Number 3
3 POSTS 0 COMMENTSPurchase PDF for $2.79
Risankizumab, an IL-23p19 Inhibitor for Psoriasis: A Review of the Current Literature
The addition of biologics that target IL-23p19 (Risankizumab) to our therapeutic armamentarium has succeeded in improving outcomes in patients with moderate-to-severe plaque psoriasis.
Management of Primary Small-Vessel Vasculitis
Small-vessel vasculitides (SVV) are a group of disorders that occur due to primarily systemic inflammation or as sequelae of an infection, malignancy, or other rheumatic disease.
Update on Drugs & Devices: May – June 2020
Update on Selumetinib capsules (Koselugo®), Crisaborole 2% ointment (Eucrisa®), Infliximab biosimilar for IV injection (Avsola™) and Baricitinib tablets (Olumiant®)